Poolbeg Pharma (LON:POLB) Given House Stock Rating at Shore Capital

Shore Capital restated their house stock rating on shares of Poolbeg Pharma (LON:POLB) in a research note published on Thursday,London Stock Exchange reports.

Poolbeg Pharma Trading Down 39.9 %

Shares of POLB stock opened at GBX 4.27 ($0.05) on Thursday. Poolbeg Pharma has a 12 month low of GBX 4.10 ($0.05) and a 12 month high of GBX 15.77 ($0.20). The stock has a market capitalization of £21.35 million, a P/E ratio of -427.00 and a beta of 2.11. The firm’s 50 day moving average is GBX 7.66 and its 200 day moving average is GBX 10.08.

About Poolbeg Pharma

Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.

Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.